Are investors shorting Cryo-Cell International?

Cryo-Cell International saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 21,900 shares, a decrease of 17.4% from the March 15th total of 26,500 shares. Based on an average daily volume of 9,900 shares, the short-interest ratio is currently 2.2 days. Currently, 0.5% of the company's shares are sold short. View Cryo-Cell International's Short Interest .

When is Cryo-Cell International's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 19th 2024. View our CCEL earnings forecast .

How were Cryo-Cell International's earnings last quarter?

Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) released its quarterly earnings data on Wednesday, February, 28th. The company reported $0.26 earnings per share for the quarter. The firm had revenue of $7.88 million for the quarter. Cryo-Cell International had a negative trailing twelve-month return on equity of 64.31% and a negative net margin of 31.02%.

Who are Cryo-Cell International's major shareholders?

Cryo-Cell International's stock is owned by many different institutional and retail investors. Top institutional investors include Massmutual Trust Co. FSB ADV (1.34%) and Rowlandmiller & PARTNERS.ADV (0.17%). View institutional ownership trends .

How do I buy shares of Cryo-Cell International?

Shares of CCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSEAMERICAN:CCEL

Cryo-Cell International (CCEL) Stock Price, News & Analysis

→ Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report (From Darwin) (Ad)

Free CCEL Stock Alerts

$7.13

-0.24 (-3.26%)

(As of 01:33 PM ET)

Compare

Today's Range: $6.82
▼
$8.05
50-Day Range: $5.03
▼
$6.14
52-Week Range: $3.62
▼
$8.15

Volume: 15,359 shs
Average Volume: 9,757 shs
Market Capitalization: $57.75 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Cryo-Cell International alerts:

Ad DTI

Start loving Mondays like this

Wouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!

Weekend after weekend!

About Cryo-Cell International Stock (NYSEAMERICAN:CCEL)

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

CCEL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CCEL Stock News Headlines

April 15, 2024 | msn.com

CCEL Stock Earnings: Cryo-Cell International Beats EPS, Misses Revenue for Q1 2024

April 15, 2024 | businesswire.com

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2024 Financial Results

April 19, 2024 | DTI (Ad)

Did you know you can now trade Bitcoin in your regular brokerage account?

You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history! That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords… Heck, you don’t even need a crypto wallet!

March 26, 2024 | markets.businessinsider.com

Cryo-Cell Plans To Explore Strategic Alternatives And Spin-off Of Celle Subsidiary

March 23, 2024 | finance.yahoo.com

Cryo-Cell International, Inc. (CCEL)

March 14, 2024 | msn.com

Unveiling the Molecular Dance Capturing the Activation of Cell Receptors through Cryo-Electron Microscopy

February 28, 2024 | businesswire.com

Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2023

February 14, 2024 | wsj.com

Cryo-Cell International Inc.

April 19, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

February 5, 2024 | seekingalpha.com

Invitae plunges amid report it may file for bankruptcy within weeks (update)

October 14, 2023 | markets.businessinsider.com

Strong Performance and Growth Potential Drive Buy Rating for Cryo-Cell International: An Analysis by Allen Klee

October 12, 2023 | finance.yahoo.com

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2023 Financial Results

August 31, 2023 | benzinga.com

Cryo-electron Microscopy Market worth $2.1 billion by 2028

July 19, 2023 | markets.businessinsider.com

Maxim Group Keeps Their Buy Rating on Cryo-Cell International (CCEL)

July 14, 2023 | finance.yahoo.com

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2023 Financial Results

May 4, 2023 | marketwatch.com

Stem Cell Services Market to Receive Overwhelming Hike in Revenues by 2030 With key Players Paragon Bioservices, APEX Biologix, VcanBio, Cryo-cell

April 28, 2023 | marketwatch.com

Cell Banking Outsourcing Market Research Analysis 2023-2031

April 27, 2023 | marketwatch.com

Global Cord Blood Stem Cells Market by [2023-2029] with Revenue Outsourcing

April 24, 2023 | msn.com

Looking Into Cryo-Cell International's Return On Capital Employed

April 21, 2023 | msn.com

CPS Technologies CEO resigns

April 21, 2023 | msn.com

CRYO-CELL International GAAP EPS of $0.09 beats by $0.13, revenue of $7.82M beats by $0.41M

April 21, 2023 | finance.yahoo.com

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2023 Financial Results

March 30, 2023 | marketwatch.com

2023-2029 Cord Stem Cell Banking Market Size and Industrial Analysis with Market Dynamics | Latest Report by Absolute Reports

March 22, 2023 | marketwatch.com

Cell Banking Outsourcing Market Outlook by 2031

March 1, 2023 | msn.com

CRYO-CELL International GAAP EPS of $0.33 beats by $0.20, revenue of $30.3M beats by $0.46M

March 1, 2023 | finance.yahoo.com

Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2022

February 22, 2023 | seekingalpha.com

CCEL Cryo-Cell International, Inc.

See More Headlines

Receive CCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cryo-Cell International and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 4/15/2024
Today: 4/19/2024
Next Earnings (Estimated): 4/19/2024
Fiscal Year End: 11/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Sector: Medical
Industry: Miscellaneous health & allied services, not elsewhere classified
Sub-Industry: N/A
Current Symbol: NYSEAMERICAN:CCEL
CUSIP: N/A
CIK: 862692
Web: www.cryo-cell.com
Phone: (813) 749-2100
Fax: 813-855-4745
Employees: 82
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.16)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-9,520,000.00
Net Margins: -31.02%
Pretax Margin: -43.94%
Return on Equity: -64.31%
Return on Assets: 5.47%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.49
Quick Ratio: 0.42

Sales & Book Value

Annual Sales: $31.34 million
Price / Sales: 1.90
Cash Flow: $0.73 per share
Price / Cash Flow: 10.06
Book Value: ($1.28) per share
Price / Book: -5.76

Miscellaneous

Outstanding Shares: 8,100,000
Free Float: 5,486,000
Market Cap: $59.70 million
Optionable: Not Optionable
Beta: 0.45

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. David I. Portnoy (Age 61)
Chairman & Co-CEO
Comp: $1.45M
Mr. Mark L. Portnoy (Age 60)
Co-CEO & Director
Comp: $990k
Ms. Jill M. Taymans (Age 54)
CFO & VP of Finance
Comp: $254.77k
Mr. Oleg Mikulinsky (Age 51)
Chief Information Officer
Comp: $382.77k
Dr. Joanne Kurtzberg M.D.
Medical Director and Member of Medical & Scientific Advisory Board

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CCEL Stock Analysis - Frequently Asked Questions

Are investors shorting Cryo-Cell International?: Cryo-Cell International saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 21,900 shares, a decrease of 17.4% from the March 15th total of 26,500 shares. Based on an average daily volume of 9,900 shares, the short-interest ratio is currently 2.2 days. Currently, 0.5% of the company's shares are sold short.
View Cryo-Cell International's Short Interest.
When is Cryo-Cell International's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, April 19th 2024.
View our CCEL earnings forecast.
How were Cryo-Cell International's earnings last quarter?: Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) released its quarterly earnings data on Wednesday, February, 28th. The company reported $0.26 earnings per share for the quarter. The firm had revenue of $7.88 million for the quarter. Cryo-Cell International had a negative trailing twelve-month return on equity of 64.31% and a negative net margin of 31.02%.

Who are Cryo-Cell International's major shareholders?: Cryo-Cell International's stock is owned by many different institutional and retail investors. Top institutional investors include Massmutual Trust Co. FSB ADV (1.34%) and Rowlandmiller & PARTNERS.ADV (0.17%).
View institutional ownership trends.
How do I buy shares of Cryo-Cell International?: Shares of CCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:CCEL) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial